IP Library Granted Patent US 12,435,109
Granted Patent B2
US 12,435,109 · App. 18/600,801 · Granted Oct 7, 2025

Compositions and methods for dissolving protein aggregates

Inventor: Chenchen Wang (Shanghai, CN)
Assignee: RJK BIOPHARMA LTD.
C07K14/001A61P25/28C12N15/86A61K38/00A61K48/00C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,109
App. No.
18/600,801
Granted
Oct 7, 2025
Kind
B2
Abstract

The present disclosure provides a polypeptide capable of dissolving protein aggregates. Also provided is a method of treating a neurodegeneration disease using the polypeptide.

Claims (52)

1. A host cell comprising a polynucleotide encoding a polypeptide, wherein the polypeptide comprises a hydrophilic segment and a hydrophobic segment, wherein the hydrophilic segment comprises a sequence selected from the group consisting of:

(SEQ ID NO: 15)

TEPQEESEEEVEEPEER,

(SEQ ID NO: 16)

TDPQDDSDDDVDDPDDR,

(SEQ ID NO: 17)

TKPQKKSKKKVKKPKKR,

(SEQ ID NO: 18)

TRPQRRSRRRVRRPRRR,

(SEQ ID NO: 19)

ELDEESEDEVEEEQEDR,

(SEQ ID NO: 20)

KEEVDEDRDVDE,

and

(SEQ ID NO: 21)

EKSEQDLE,

or a sequence having at least 90% identity thereto,

wherein the hydrophobic segment comprises a sequence selected from the group consisting of:

(SEQ ID NO: 22)

TFYDQTVSNDL,

(SEQ ID NO: 23)

ANSAYYDAHPVTNGI,

(SEQ ID NO: 24)

PPQTAAREATSIPGFPAEGAIPLPV,

and

(SEQ ID NO: 25)

EGEVAEEPNSRP,

or a sequence having at least 90% identity thereto,

wherein the hydrophilic segment is at the N-terminus and the hydrophobic segment is at the C-terminus,

wherein the polypeptide has a length of 20-60 amino acid residues, and

wherein the polypeptide is capable of dissolving a protein aggregate.

2. The host cell of claim 1 , wherein the protein aggregate is fused in sarcoma (FUS) aggregate, TAR DNA-binding protein 43 (TDP43) aggregate, T-cell intracellular antigen-1 (TIA1) aggregate, chromosome 9 open reading frame 72 (C9orf72) aggregate or a combination thereof.

3. A host cell comprising a polynucleotide encoding a polypeptide, wherein the polypeptide comprises a hydrophilic segment and a hydrophobic segment, wherein the polypeptide comprises a sequence selected from the group consisting of:

(SEQ ID NO: 1)

TEPQEESEEEVEEPEERQQTPEVVPDDSGTFYDQTVSNDLE,

(SEQ ID NO: 2)

TDPQDDSDDDVDDPDDRQQTPDVVPDDSGTFYDQTVSNDLD,

(SEQ ID NO: 3)

TKPQKKSKKKVKKPKKRQQTPKVVPDDSGTFYDQTVSNDLK,

(SEQ ID NO: 4)

TRPQRRSRRRVRRPRRRQQTPRVVPDDSGTFYDQTVSNDLR,

(SEQ ID NO: 8)

ELDEESEDEVEEEQEDRQPSPEPVQENANSAYYDAHPVTNGIE,

(SEQ ID NO: 9)

KEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPG

FPAEGAIPLPV,

and 

(SEQ ID NO: 10)

EGEVAEEPNSRPQEKSEQDLE,

or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue difference therefrom, and

wherein the polypeptide is capable of dissolving a protein aggregate.

4. The host cell of claim 3 , wherein the protein aggregate is fused in sarcoma (FUS) aggregate, TAR DNA-binding protein 43 (TDP43) aggregate, T-cell intracellular antigen-1 (TIA1) aggregate, chromosome 9 open reading frame 72 (C9orf72) aggregate or a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2024
From: WANG, CHENCHEN
To: REJUKON BIOPHARM INC.
Reel/Frame 066743/0633 →
Priority Claims (1)
CN 202010796060.4 · Aug 10, 2020 · national
Continuity (3)
Continuation 17887501 · Aug 14, 2022
Continuation PCTCN2021111683 · Aug 10, 2021
Related Publication 20240294575A1 · Sep 5, 2024
References Cited (1)
US 11970517B2 · Wang · 2024 [cited by examiner]